DrugPatentWatch Database Preview

Details for Patent: 8,623,826

« Back to Dashboard

Which drugs does patent 8,623,826 protect, and when does it expire?

Patent 8,623,826 protects AKYNZEO and is included in one NDA.

This patent has sixty-eight patent family members in forty-one countries.

Summary for Patent: 8,623,826

Title:	Compositions and methods for treating centrally mediated nausea and vomiting
Abstract:	Provided are methods for treating nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery, comprising the co-administration of netupitant, palonosetron and dexamethasone.
Inventor(s):	Trento; Fabio (Como, IT), Cantoreggi; Sergio (Cagiallo, CH), Rossi; Giorgia (Como, IT), Cannella; Roberta (Varese, IT), Bonadeo; Daniele (Varese, IT)
Assignee:	Helsinn Healthcare S.A. (Lugano/Pazallo, CH)
Application Number:	13/077,462
Patent Claim Types: see list of patent claims	Use; Delivery;

Drugs Protected by US Patent 8,623,826

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Helsinn Hlthcare	AKYNZEO	netupitant; palonosetron hydrochloride	CAPSULE;ORAL	205718-001	Oct 10, 2014		RX	Yes	Yes

International Family Members for US Patent 8,623,826

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	3083
Australia	2010320598
Brazil	112012011485
Canada	2778301